News

A new multi-institutional study found that a second cytoreductive surgery (CRS) with or without HIPEC may be a safe option for carefully selected patients with recurrent colorectal cancer that has spread to the peritoneum. Patients who underwent repeat surgery had similar complication rates and lived longer than those treated with systemic therapy or supportive care alone.

A new study examined how often incisional hernias occur after cytoreductive surgery (CRS) and HIPEC for colorectal and appendiceal cancers. Researchers found that patients with a history of prior open abdominal surgery or a previous hernia had the highest risk, highlighting the importance of individualized surgical planning, recovery, and long-term follow-up.

Peritoneal metastases are difficult to treat because standard IV chemotherapy often cannot reach tumors inside the abdomen effectively. This review explores NIPS, an approach that combines intravenous chemotherapy with repeated chemotherapy delivered directly into the abdominal cavity. Early research—especially in gastric cancer—suggests this strategy may improve disease control, increase eligibility for surgery, and help some patients live longer.

This study suggests that the biology of a colorectal cancer tumor may influence how well it responds to different HIPEC chemotherapy drugs. Researchers found that the CMS4 subtype appeared particularly sensitive to mitomycin C and irinotecan, raising the possibility that future HIPEC treatments could be tailored to a patient's specific tumor characteristics.

Al Mahrizi, A.D., Mossolem, F., Major, E. et al. Prophylactic Intraperitoneal Chemotherapy with Platinum Agents Following Curative Resection for Colorectal Cancer: A Systematic Review and Meta-Analysis. Ann Surg Oncol 33, 2972–2984 (2026). https://doi.org/10.1245/s10434-025-18903-4 What is this study about? This research looked at a strategy to help prevent colorectal (colon and rectal) cancer from coming back after surgery. Even when surgery successfully removes all visible

Amblard I, Mercier F, Bartlett DL, Ahrendt SA, Lee KW, Zeh HJ, Levine EA, Baratti D, Deraco M, Piso P, Morris DL, Rau B, Tentes AAK, Tuech JJ, Quenet F, Akaishi E, Pocard M, Yonemura Y, Lorimier G, Delroeux D, Villeneuve L, Glehen O, Passot G; PSOGI and BIG RENAPE working groups. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups. E

Every March, during Colorectal Cancer Awareness Month , communities, clinicians, caregivers, and survivors come together to raise awareness about colorectal cancer—one of the most common cancers in the United States. While progress in prevention, screening, and treatment has saved lives, this disease remains a critical public health issue. What Is Colorectal Cancer? Colorectal cancer begins in the colon or rectum, which are parts of the lower digestive tract. It is one of the

Predictors of Peritoneal Surface Recurrence and Quantitative Association with Time to Relapse After Complete CRS/HIPEC for Colorectal Peritoneal Metastasis. (2026). Cancers. 18. 299. DOI: 10.3390/cancers18020299 . Understanding Recurrence After CRS/HIPEC for Colorectal Cancer Spread to the Abdomen When colorectal cancer spreads to the lining of the abdomen (called peritoneal metastasis ), one treatment option for carefully selected patients is cytoreductive surgery (CRS) com

This research study explored outcomes for people with colorectal cancer that had spread to two places at the same time: the lining of the abdomen (called the peritoneum), and the liver.

This study focused on a key challenge: in many bowel cancers, especially stromal-rich types (those with lots of supporting tissue, or stromal cells, around the tumor), immune therapies aren’t working as well as hoped. Researchers investigated how certain “support” cells within the tumor (called stromal cells) may be actively helping the cancer by suppressing the body’s immune system. Then they investigated how to turn the immune system back on again in these hard-to-treat can

By Sonya Walker October 2025 (Col. Ret.) Dr. Lawrence Henry's journey is a testament to the power of resilience, self- advocacy, and...

By Christine Strovink New York May 2024 From video transcript: It started with an emergency. I had to have emergency surgery. They...

One day people will watch this story.

by Joe Finn September 23, 2023 Joe had some pains which prompted him to visit the hospital. There, he found out he had cancer. With some...

by Paul Kalusa September 23, 2023 Paul was diagnosed with stage IV colon cancer two months after his daughter was born, but by finding...